Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (21-30 of 155) with videos related to

Pageof 16
Sort By:
Investigational New Drugs|January 1, 1994
Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinomaT M Law, P Mencel, R J Motzer
Investigational New Drugs|January 1, 1994
Phase II trial of topotecan in patients with advanced renal cell carcinomaT M Law, D H Ilson, R J Motzer
Current Therapy in Endocrinology and Metabolism|January 1, 1994
Germ cell tumorsD F Bajorin, R J Motzer, G J Bosl
Investigational New Drugs|November 1, 1992
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCTB A Murphy, R J Motzer, G J Bosl
The Urologic Clinics of North America|September 5, 1998
Poor-risk germ cell tumors. Recent developmentsP M Dodd, R J Motzer, D F Bajorin
Cancer|September 1, 1990
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patientsR J Motzer, N L Geller, G J Bosl
Current Therapy in Endocrinology and Metabolism|January 1, 1997
Germ cell tumorsD F Bajorin, R J Motzer, G J Bosl
Seminars in Oncology|April 1, 1992
"Poor-risk" germ cell tumors: current progress and future directionsR J Motzer, D F Bajorin, G J Bosl
The New England Journal of Medicine|September 19, 1996
Renal-cell carcinomaR J Motzer, N H Bander, D M Nanus
Cancer|April 1, 1994
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinomaP J Mencel, L M DeAngelis, R J Motzer
Pageof 16

Showing results (21-30 of 155) with videos related to

Sort By:
Pageof 16
Investigational New Drugs|January 1, 1994
Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinomaT M Law, P Mencel, R J Motzer
Investigational New Drugs|January 1, 1994
Phase II trial of topotecan in patients with advanced renal cell carcinomaT M Law, D H Ilson, R J Motzer
Current Therapy in Endocrinology and Metabolism|January 1, 1994
Germ cell tumorsD F Bajorin, R J Motzer, G J Bosl
Investigational New Drugs|November 1, 1992
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCTB A Murphy, R J Motzer, G J Bosl
The Urologic Clinics of North America|September 5, 1998
Poor-risk germ cell tumors. Recent developmentsP M Dodd, R J Motzer, D F Bajorin
Cancer|September 1, 1990
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patientsR J Motzer, N L Geller, G J Bosl
Current Therapy in Endocrinology and Metabolism|January 1, 1997
Germ cell tumorsD F Bajorin, R J Motzer, G J Bosl
Seminars in Oncology|April 1, 1992
"Poor-risk" germ cell tumors: current progress and future directionsR J Motzer, D F Bajorin, G J Bosl
The New England Journal of Medicine|September 19, 1996
Renal-cell carcinomaR J Motzer, N H Bander, D M Nanus
Cancer|April 1, 1994
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinomaP J Mencel, L M DeAngelis, R J Motzer
Pageof 16